Researchers at Cedars-Sinai have developed a new artificial intelligence tool, named BRIDGE, that could transform how oncologists select presurgical treatments for breast cancer patients. The tool, detailed in the journal Annals of Oncology alongside early validation data, analyzes genetic signals within a tumor to identify its molecular subtypes rather than categorizing the entire mass as a single type.
Breast cancer is not a single disease but comprises several subtypes, each responding differently to therapies. Traditional methods often classify a tumor based on its dominant characteristics, potentially overlooking critical genetic variations that could influence treatment response. BRIDGE addresses this by reading the genetic signals inside a tumor to detect which subtypes are present, enabling a more personalized approach to presurgical therapy.
The tool builds on recent advances in cancer research, including work by companies such as Calidi Biotherapeutics Inc. (NASDAQ: CLDI), which focuses on developing innovative cancer treatments. However, BRIDGE specifically targets the challenge of treatment selection, a critical step that can impact patient outcomes.
Presurgical therapy, also known as neoadjuvant therapy, is given before surgery to shrink tumors and improve surgical outcomes. Choosing the right therapy is crucial, as it can increase the chances of a complete pathological response, where no cancer cells remain in the breast tissue after treatment. BRIDGE aims to provide clinicians with a data-driven tool to make this decision more accurately.
The implications for patients and the healthcare industry are significant. By identifying the precise subtypes present in a tumor, BRIDGE could help avoid ineffective treatments, reduce side effects, and improve survival rates. For healthcare providers, the tool offers a way to optimize treatment plans, potentially reducing costs associated with trial-and-error approaches.
The validation data published in Annals of Oncology suggests that BRIDGE can accurately predict which patients are likely to benefit from specific therapies. While the tool is still in early stages, its development represents a step forward in precision oncology, where treatments are tailored to the genetic profile of each patient's cancer.
As AI continues to penetrate healthcare, tools like BRIDGE highlight the potential for machine learning to analyze complex biological data and provide actionable insights. For business leaders in the technology and healthcare sectors, this development underscores the growing importance of AI in medical decision-making and the need for partnerships between research institutions and technology companies.
Further details on the BRIDGE tool and its validation can be found in the published study. The research was conducted at Cedars-Sinai, a renowned medical center, and the tool is expected to undergo additional clinical testing before widespread adoption.
